ERBB2 and triple-negative breast carcinoma: Increased TIL levels predicted a higher rate of response to neoadjuvant chemotherapy in all molecular subtypes and was also associated with a survival benefit in human epidermal growth factor receptor 2-positive and triple-negative breast cancer.